CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.
Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Recent innovations in DNA-modifying will revolutionize the treatment of many diseases and prompt crucial discussions.
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Professor and HHMI Investigator Zachary Lippman and his colleagues are exploring how non-coding DNA segments, known as ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the ...